

Sumitomo Chemical India

India | Fertilizers & Agricultural Chemicals | Result Update



28 January 2026

Steep stock price correction warrants a relook

Sumitomo Chemical India (SUMICHEM IN) results were in line with our estimates after adjusting for the impact of a discontinued business. For continuing business, top line and EBITDA were flat. Headwinds continue to affect domestic business and exports. We expect a gradual recovery in Q4, which can pick up steam in FY27. SUMICHEM announced fresh capex of INR 1.5bn, which will be followed up with additional investments, for high potential patented molecules from the parent's product pipeline. Weakness in the domestic agrochemicals industry and unstable recovery in global markets has led to a 21% correction in the stock price in the past three months and 40% correction from the peak of INR 652. We believe this is a good entry price to add SUMICHEM as earnings recovery is around the corner. We retain **Buy** with a lower TP of INR 605 based on 42x H1FY28E EPS of INR 14.4.

Kharif inventory overhang drags domestic business: Domestic revenue declined 21% YoY to INR 3.7bn in Q3FY26, adversely affected by weaker-than-expected Kharif season, due to persistent rains in October. Rabi demand lagged expectations as delayed Monsoon withdrawal pushed back sowing activity. Continued softness in agri-input demand led to cautious distributor purchases amid tight rural liquidity. Overhang of Kharif inventory further weighed on volume. We expect growth to pick up pace from Q4, driven Rabi season demand and Kharif season placements. SUMICHEM remains focused on driving ground-level demand for high-margin specialty products and sustaining cost discipline.

Capex to strengthen manufacturing footprints: SUMICHEM has approved capex for a Greenfield plant at its Dahej site to manufacture a herbicides intermediate for supply to the parent company with an investment of INR 1.5bn, with likely commercialization in Q2FY29. Initial operations will leverage process know-how from the parent, with SUMICHEM driving subsequent process optimization and cost efficiency. In addition, the company has approved INR 0.1bn capex for fitment at the Tarapur facility to manufacture one fungicide and one herbicide molecule, utilizing existing infra to enhance asset utilization and support supplies to the parent firm. The project is set for commercialization in Q4FY28. Brownfield projects at Bhavnagar with investment of ~INR 0.6bn is underway, underscoring the company's strategy to scale up manufacturing capabilities across three locations.

Strong focus on products-led growth: The company continues to drive growth through product-led initiatives, with Excalia Max (Indiflin) and Lentigo (Imazosulfuron) progressing as planned. Yunico, Yunico Flow (Chlorantraniliprole), and Ormie (Tebuconazole + Validamycin) showed good traction. Topgrain, a new bio-rational product, has secured registration and is slated for launch in the upcoming Kharif season.

Retain Buy with a lower TP of INR 605: Despite near-term headwinds due to adverse weather, the structural growth story is intact, via: 1) rising share of the parent's business, 2) exporting generics molecules to affiliate companies, and 3) proprietary product launch, domestically. We lower our FY26-28E EBITDA by 4-5%, dragged by the seasonal domestic business. Hence, we lower our TP to INR 605 from INR 633 on 42x (unchanged) H1FY28E P/E. We retain **Buy**.

Key financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	28,439	31,485	32,458	36,895	40,829
YoY (%)	(19.0)	10.7	3.1	13.7	10.7
EBITDA (INR mn)	4,746	6,321	6,849	8,025	9,146
EBITDA margin (%)	16.7	20.1	21.1	21.8	22.4
Adj PAT (INR mn)	3,695	5,055	5,638	6,672	7,701
YoY (%)	(26.4)	36.8	11.5	18.4	15.4
Fully DEPS (INR)	7.4	10.1	11.3	13.4	15.4
RoE (%)	15.3	18.9	18.1	18.6	18.4
RoCE (%)	17.1	21.2	20.0	20.2	19.8
P/E (x)	54.7	40.0	35.8	30.3	26.2
EV/EBITDA (x)	40.3	30.3	27.9	23.8	20.9

Note: Pricing as on 27 January 2026; Source: Company, Elara Securities Estimate

Rating: Buy

Target Price: INR 605

Upside: 49%

CMP: INR 405

As on 27 January 2026

Key data

Bloomberg	SUMICHEM IN
Reuters Code	SUMH.NS
Shares outstanding (mn)	499
Market cap (INR bn/USD mn)	202/2,202
EV (INR bn/USD mn)	191/2,085
ADTV 3M (INR mn/USD mn)	128/1
52 week high/low	665/396
Free float (%)	25

Note: as on 27 January 2026; Source: Bloomberg

Price chart



Source: Bloomberg

Shareholding (%)	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Promoter	75.0	75.0	75.0	75.0
% Pledge	0.0	0.0	0.0	0.0
FII	3.6	3.7	3.7	3.4
DII	8.2	8.2	8.5	8.7
Others	13.2	13.2	12.9	13.0

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(3.0)	1.4	10.3
Sumitomo Chemical India	(21.9)	(30.8)	(20.0)
NSE Mid-cap	(3.8)	(0.4)	10.3
NSE Small-cap	(11.5)	(11.7)	(0.5)

Source: Bloomberg

Prashant Biyani

Fertilizers & Agricultural Chemicals,
Hotels, Sugar
+91 22 6164 8581
prashant.biyani@elaracapital.com

Associate
Yashi Jain
yashi.jain@elaracapital.com



Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	28,439	31,485	32,458	36,895	40,829
Gross Profit	10,689	12,896	13,470	15,127	16,740
EBITDA	4,746	6,321	6,849	8,025	9,146
EBIT	4,124	5,660	6,220	7,252	8,289
Interest expense	51	59	70	50	50
Other income	957	1,201	1,465	1,758	2,110
Exceptional/ Extra-ordinary items	-	-	(152)	-	-
PBT	5,029	6,802	7,463	8,960	10,349
Tax	1,332	1,738	1,957	2,258	2,608
Minority interest/Associates income	(2)	(9)	(20)	(30)	(40)
Reported PAT	3,695	5,055	5,486	6,672	7,701
Adjusted PAT	3,695	5,055	5,638	6,672	7,701
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	24,416	29,011	33,192	38,634	45,070
Minority Interest	30	39	45	50	55
Trade Payables	4,300	4,894	4,891	5,559	6,152
Provisions & Other Current Liabilities	3,701	4,758	4,544	5,139	5,668
Total Borrowings	5	-	-	-	-
Other long term liabilities	680	942	918	962	1,002
Total liabilities & equity	33,132	39,644	43,589	50,345	57,947
Net Fixed Assets	4,982	4,986	5,069	6,117	6,780
Goodwill	-	-	-	-	-
Intangible assets	870	862	882	902	922
Business Investments / other NC assets	552	3,593	3,281	3,460	3,376
Cash, Bank Balances & treasury investments	7,103	6,019	9,958	13,246	18,280
Inventories	6,104	7,037	7,114	8,086	8,949
Sundry Debtors	7,159	7,834	8,003	9,097	10,068
Other Current Assets	6,362	9,314	9,281	9,436	9,574
Total Assets	33,132	39,644	43,589	50,345	57,947
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	7,404	4,341	4,337	4,172	5,389
Capital expenditure	(637)	(295)	(1,106)	(1,800)	(1,500)
Acquisitions / divestitures	-	-	-	-	-
Other Business cashflow	(3,315)	(2,808)	1,465	1,758	2,110
Free Cash Flow	3,451	1,239	4,695	4,131	5,999
Cashflow from Financing	(4,130)	(2,322)	(756)	(843)	(966)
Net Change in Cash / treasury investments	(678)	(1,084)	3,939	3,288	5,034
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	5.3	1.2	1.4	1.6	1.8
Book value per share (INR)	48.9	58.1	66.5	77.4	90.3
RoCE (Pre-tax) (%)	17.1	21.2	20.0	20.2	19.8
ROIC (Pre-tax) (%)	24.7	28.0	26.9	29.8	31.7
ROE (%)	15.3	18.9	18.1	18.6	18.4
Asset Turnover (x)	5.8	6.3	6.5	6.6	6.3
Net Debt to Equity (x)	(0.3)	(0.2)	(0.3)	(0.3)	(0.4)
Net Debt to EBITDA (x)	(1.5)	(1.0)	(1.5)	(1.7)	(2.0)
Interest cover (x) (EBITDA/ int exp)	92.9	107.9	97.8	160.5	182.9
Total Working capital days (WC/rev)	215.1	250.4	284.5	307.0	329.2
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	54.7	40.0	35.8	30.3	26.2
P/Sales (x)	7.1	6.4	6.2	5.5	4.9
EV/ EBITDA (x)	40.3	30.3	27.9	23.8	20.9
EV/ OCF (x)	25.8	44.1	44.1	45.8	35.5
FCF Yield	1.8	0.6	2.5	2.2	3.1
Price to BV (x)	8.3	7.0	6.1	5.2	4.5
Dividend yield (%)	1.3	0.3	0.3	0.4	0.5

Note: Pricing as on 27 January 2026; Source: Company, Elara Securities Estimate

Exhibit 1: Quarterly financials

Standalone financials (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance (%)	9MFY26	9MFY25	YoY (%)
Net sales	5,518	6,224	(11.4)	9,144	(39.7)	6,147	(10.2)	25,143	24,256	3.7
Raw Materials	2,950	3,656	(19.3)	5,243	(43.7)	3,596	(18.0)	14,720	14,381	2.4
% of Net Sales	53.5	58.7	(527)bp	57.3	(387)bp	58.5	(504)bp	58.5	59.3	(74)bp
Employee Cost	623	633	(1.5)	640	(2.6)	646	(3.5)	1,926	1,860	3.6
Other Expenses	989	925	6.9	1,092	(9.5)	934	5.9	3,175	2,962	7.2
Total Expenditure	4,562	5,213	(12.5)	6,975	(34.6)	5,176	(11.9)	19,821	19,202	3.2
EBITDA	956	1,011	(5.5)	2,170	(55.9)	971	(1.6)	5,322	5,054	5.3
Margin (%)	17.3	16.2	108bp	23.7	(640)bp	15.8	152bp	21.2	20.8	33bp
Depreciation	158	183	(13.6)	159	(0.5)	160	(1.3)	466	477	(2.1)
EBIT	798	828	(3.7)	2,011	(60.3)	811	(1.7)	4,855	4,577	6.1
Interest	17	15	11.2	19	(12.7)	20	(17.0)	50	35	42.5
Other Income	368	313	17.7	387	(4.9)	391	(5.8)	1,141	881	29.6
Exceptional Items	(152)	-	NA	-	NA	-	NA	(152)	-	NA
PBT	1,301	1,126	15.6	2,379	(45.3)	1,182	10.1	6,099	5,423	12.5
Tax	249	283	(11.9)	600	(58.4)	298	(16.3)	1,470	1,388	5.9
Tax Rate (%)	19.2	25.1	(597)bp	25.2	(606)bp	25.2	(604)bp	24.1	25.6	(149)bp
RPAT	748	843	(11.3)	1,779	(57.9)	884	(15.4)	4,325	4,035	7.2
APAT	900	843	6.8	1,779	(49.4)	884	1.8	4,477	4,035	10.9
Adj EPS (INR)	1.8	1.7	6.8	3.6	(49.4)	1.8	1.8	9.0	8.1	10.9

Source: Company, Elara Securities Estimate

Working capital days rise on inventory buildup: Net working capital increased by 17 days to 135, due to inventory buildup ahead of the Rabi season. Inventory holding rose to 126 days from 114. This was offset by an improvement in receivable days to 75 from 93, underscoring effective collection efforts and tighter credit discipline despite muted demand conditions. Payable days reduced to 66 from 89, reflecting a normalization in supplier credit terms. Collections dropped 3% to INR 781mn, and cash rose 30% YoY to INR 22bn with cash per share at INR 43.

Product mix change leads to margin expansion: SUMICHEM discontinues the animal nutrition products distribution (AND) business in India, which resulted in a revenue impact of INR 720mn in Q3FY26. The AND business carried low single-digit margin, and management says such arrangements will be undertaken only in exceptional situations. Gross margin expanded by 527bp YoY to 46.5%, supported by discontinuation of low-margin AND business, a favorable product mix, and disciplined pricing, which helped offset the impact of subdued volume.

Exhibit 2: Insecticides segment up 9.4% YoY

Product-wise growth (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Insecticides	(41.0)	6.4	3.1	11.8	12.3	(2.7)	26.0	(3.3)	9.4
Herbicides	(52.1)	(34.8)	18.3	(20.2)	27.2	9.4	26.0	(17.3)	4.6
PGR	0.5	52.3	31.3	17.6	(9.6)	59.9	10.3	(21.7)	(27.5)
Metal Phosphides	12.8	2.0	14.9	6.6	14.0	2.1	26.0	22.6	2.2
Fungicides	(3.5)	(13.3)	101.0	22.5	112.2	(12.1)	(10.0)	19.4	(38.1)
AND & EHD	10.0	95.3	2.1	59.4	(8.8)	(32.8)	73.3	(21.1)	(66.9)

Source: Company, Elara Securities Research

Exhibit 3: Insecticides account for 48% revenue in Q3FY26

Product-wise breakdown (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Insecticides	40.0	44.9	35.0	42.4	39.0	43.6	35.0	43.6	48.1
Herbicides	13.0	12.5	34.0	19.1	14.3	13.7	34.0	16.8	16.9
PGR	14.0	6.9	8.0	13.6	11.0	11.0	7.0	11.3	9.0
Metal Phosphides	11.0	12.4	8.0	6.1	10.9	12.6	8.0	8.0	12.6
Fungicides	7.0	11.4	7.0	10.7	12.9	10.0	5.0	13.6	9.0
AND & EHD	15.0	13.4	8.0	8.0	11.9	9.0	11.0	6.7	4.4

Source: Company, Elara Securities Research

Exhibit 4: Domestic business declines by 21.3% YoY

Geographical sales growth (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
India	(16.6)	(3.8)	13.5	(4.4)	7.0	15.0	29.0	(4.2)	(21.3)
Africa	(44.7)	13.8	53.1	92.3	32.1	(25.4)	(5.5)	31.7	(2.9)
Japan	(64.1)	14.9	NA	199.4	72.8	(71.6)	NA	(13.0)	152.9
Asia	(28.3)	(289.7)	72.3	(38.5)	15.2	5.5	(16.0)	64.6	190.6
Europe	79.7	3.5	14.9	983.5	(54.0)	(1.4)	(37.0)	(52.9)	(55.7)
South America	(84.2)	(11.7)	72.3	284.2	318.4	(31.0)	(37.0)	(38.3)	(30.4)
North America	(28.3)	3.5	NA	NA	NA	358.4	NA	NA	NA

Source: Company, Elara Securities Research

Exhibit 5: India contributes 67% to sales mix in Q3FY26

Geographical sales breakdown (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
India	81.0	58.3	85.0	81.3	75.2	67.1	87.0	82.7	66.8
Africa	6.0	11.6	4.0	2.1	6.9	8.6	3.0	3.0	7.6
Japan	2.0	10.6	-	5.6	3.0	3.0	3.0	5.1	8.6
Asia	2.0	6.3	3.0	1.1	2.0	6.6	2.0	2.0	6.6
Europe	5.0	2.0	2.0	2.0	2.0	2.0	1.0	1.0	1.0
South America	3.0	11.6	6.0	7.9	10.9	8.0	3.0	5.1	8.6
North America	1.0	1.0	-	-	-	4.6	1.0	1.0	1.0

Source: Company, Elara Securities Research

Exhibit 6: Exports business grows 19% YoY

Sales Growth (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Domestic	(16.6)	(3.8)	13.5	(4.4)	7.0	15.0	29.0	(4.2)	(21.3)
Exports	(55.1)	34.2	23.1	134.1	50.1	(23.6)	9.2	(13.0)	18.8

Source: Company, Elara Securities Research

Exhibit 7: Domestic business contributes 67% to sales mix in Q3FY26

Sales breakdown (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Domestic	81.0	58.3	85.0	81.3	75.2	67.1	87.0	82.7	66.8
Export	19.0	43.1	15.0	18.7	24.8	32.9	13.0	17.3	33.2

Source: Company, Elara Securities Research

Exhibit 8: Branded segment contributes 91% to domestic sales in Q3FY26

Domestic sales breakdown (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Bulk	26.6	31.7	21.0	15.3	30.6	31.8	22.0	17.6	8.9
Branded	73.4	68.3	79.0	84.7	69.4	68.2	78.0	82.4	91.1

Source: Company, Elara Securities Research

Exhibit 9: Bulk segment contributes 66% to exports sales in Q3FY26

Exports sales breakdown (%)	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Bulk	61.0	67.0	62.0	78.9	72.0	56.5	66.0	66.0	66.0
Branded	39.0	33.0	38.0	21.1	28.0	43.5	34.0	34.0	34.0

Source: Company, Elara Securities Research

Exhibit 10: Valuation

(INR)	
EPS – FY27E	13.4
EPS – FY28E	15.4
Implied EPS- H1FY28E	14.4
Target multiple (x)	42.0
Target price	605


Source: Elara Securities Estimate

Exhibit 11: Changes in estimates

(INR mn)	Earlier			Revised			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net Sales	34,340	38,972	43,123	32,458	36,895	40,829	(5.5)	(5.3)	(5.3)
EBITDA	7,160	8,476	9,660	6,849	8,025	9,146	(4.3)	(5.3)	(5.3)
EBITDA Margin (%)	20.9	21.8	22.4	21.1	21.8	22.4	25bp	0bp	0bp
Adjusted PAT	5,834	6,989	8,059	5,942	6,672	7,701	1.8	(4.5)	(4.4)
EPS (INR)	11.7	14.0	16.1	11.9	13.4	15.4	1.8	(4.5)	(4.4)
Target Price (INR)	633			605			(4.5)		

Source: Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
01-Aug-2023	Accumulate	457	408
30-Oct-2023	Accumulate	401	381
02-Feb-2024	Accumulate	423	400
28-May-2024	Accumulate	472	449
26-Jul-2024	Accumulate	569	505
29-Oct-2024	Accumulate	600	552
28-Jan-2025	Buy	685	506
28-May-2025	Buy	666	510
05-Aug-2025	Accumulate	698	638
28-Oct-2025	Buy	633	512
27-Jan-2026	Buy	605	405

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the “Recipient”) only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/and> Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
 One International Center, Tower 3,
 21st Floor, Senapati Bapat Marg,
 Elphinstone Road (West)
 Mumbai – 400 013, India
 Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
 6th Floor, The Grove,
 248A Marylebone Road,
 London, NW1 6JZ,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Securities Inc.
 230 Park Avenue, Suite 2415,
 New York, NY 10169, USA
 Tel: +1 212 430 5870
 Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
 One Marina Boulevard,
 Level 20,
 Singapore 018989
 Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#).

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
 Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509